Genomic stratification of multiple myeloma treated with novel agents

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 202-207

  Jiang, Allan ^a   Reece, Donna ^a   Chang, Hong ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cytogenetics; Myeloma; Prognostication

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; I KAPPA B; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEIN P53; THALIDOMIDE; VINCRISTINE;

CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DRUG EFFICACY; HUMAN; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMOSOME ABERRATIONS; GENOMICS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; THALIDOMIDE;

EID: 84856092448     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.608449     Document Type: Review

References (58)

1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009;374:324-339.
2. Jemal A, Siegal R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Avet-Loiseau H. Role of genetics in prognostication of myeloma. Best Res Clin Haematol 2007;20:625-635.
4. Yeung J, Chang H. Genomic aberrations anDimmunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008;61:832-836. (Pubitemid 351969727)
5. Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocation into immunoglobulin heavy chain switch regions in multiple myelomas. Proc Natl Acad Sci USA 1996;93:13931-13936. (Pubitemid 26424223)
6. Avet-Loiseau H, Brigaudeau C, Talmant P, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fl uorescence in situ hybridization. Genes Chromosomes Cancer 1999;24:9-15. (Pubitemid 28544457)
7. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classifi cation of multiple myeloma. J Clin Oncol 2005;23:6333-6338. (Pubitemid 46218843)
8. Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011;117:2009 - 2011.
9. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489-3495. (Pubitemid 46572539)
10. Fonseca R, Bloo DE, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575. (Pubitemid 36857829)
11. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patientSundergoing autologous stem cell transplant. Br J Haematol 2004;125:64-68. (Pubitemid 38453279)
12. Chang H, Qi XY, Stewart AK. t(11;14) does not predict long-term survival in myeloma. Leukemia 2005;19:1078-1079. (Pubitemid 40862022)
13. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classifi cation of multiple myeloma: spotlight review. Leukemia 2009;23:2210-2221.
14. Chang H, Bouman D, Boerkoel CF, et al. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fl uorescence in situ hybridization. Leukemia 1999;13:105-109. (Pubitemid 29043724)
15. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identifi ed by FISH analysis and serum
16. [beta]2- microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-1571.
17. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041-1047. (Pubitemid 35025967)
18. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic signifi cance of interphase fl uorescence in situ hybridization detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002;62:715-720. (Pubitemid 34126946)
19. Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detecteDin metaphase and/or interphase cells at diagnosis of multiple myeloma. Blood 2005;106:3553-3558. (Pubitemid 41609193)
20. Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fl uorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358-360. (Pubitemid 40053104)
21. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-1011.
22. Chang H, Sloan S, Li D, et al. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280-284. (Pubitemid 39468940)
23. Sawyer JR, Waldron JA, Jagannath S, et al. Cytogenetic fi ndings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-49.
24. Shaughnessy J. Amplifi cation and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10:117-126. (Pubitemid 41829514)
25. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fl uorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma anDis related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108: 1724-1732. (Pubitemid 44316143)
26. Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with CKS1B gene amplifi cation have a shorter progression-free survival postautologous stem cell transplantation. Br J Haematol 2006;135:486-491. (Pubitemid 44583412)
27. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fl uorescent in situ hybridization anDincrease CKS1B expression in myeloma. Leukemia 2006;20:2034-2040. (Pubitemid 44614894)
28. Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548-554.
29. Zhan F, Colla S, Wu X, et al. CKS1B, overexpresseDin aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007:109:4995-5001. (Pubitemid 46827799)
30. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic signifi cance of copy-number alterations in multiple myeloma. J Clin Oncol 2009;27:4585-4590.
31. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNPbased mapping anDexpression array reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733-1743. (Pubitemid 44316144)
32. Chang H, Qi X, Jiang A, et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010;45:117-121.
33. Mailand N, Lukas C, Kaiser BK, et al. Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. Nat Cell Biol 2002;4:317-322. (Pubitemid 34308859)
34. Paulsen MT, Starks AM, Derheimer FA, et al. The p53-targeting human phosphatase hCdc14A interacts with the CdkI/cyclin B complex anDis diff erentially expresseDin human cancers. Mol Cancer 2006;5:25.
35. Leone PE, Walker BA, Jenner MW, et al. Deletions of CDKN2C in multiple myeloma: biological and clinicaLimplications. Clin Cancer Res 2008;14:6033-6041.
36. Chng WJ, Gertz MA, Chung TH, et al. Correlation between arraycomparative genomic hybridization-defi ned genomic gains and losses and survival: identifi cation of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010;24:833-842.
37. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360. (Pubitemid 38579481)
38. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)
39. J agannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157. (Pubitemid 44921846)
40. S agaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of chromosome 13q-deletion. Leukemia 2007;21:164-168. (Pubitemid 44921848)
41. Chang H, Trieu Y, Qi X, et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779-782. (Pubitemid 46855891)
42. Chang H, Trieu Y, Qi X, et al. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse Effect of 1q21 gains. Leuk Res 2011;35:95-98.
43. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: effi cacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-3525.
44. S an Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
45. Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009;147:347-351.
46. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4634.
47. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525-4530. (Pubitemid 34627223)
48. Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell anDits bone marrow microenvironment. Semin Oncol 2001;28:607-612. (Pubitemid 33134420)
49. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87:1166-1172. (Pubitemid 35418112)
50. Richardson PG, Bloo DE, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-3464.
51. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132. (Pubitemid 350146107)
52. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142. (Pubitemid 350146108)
53. Reece D, Song KW, Fu T, et al. Infl uence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse Effect of deletion 17p13. Blood 2009;114:522-525.
54. Avet-Loiseau H, Soulier J, Fermand JP, et aLimpact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623-628.
55. Chang H, Jiang A, Qi C, et al. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma 2010;51:2084-2091.
56. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24:1769-1778.
57. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratifi cation on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114: 518-521.
58. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-686.